Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 111

recruiting
3 968
countries
28
conditions
2 103

10 282 trials match your criteria

Study on Atorvastatin's Role in Enhancing Immunotherapy for Patients with Triple Negative Breast Cancer and Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin

Study on the Safety and Effectiveness of BNT327 and Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer After Chemoimmunotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:BNT327

Efficacy of 177Lu-DOTATATE as Adjuvant Therapy After Surgery for Stage III Small Intestinal Neuroendocrine Tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lutetium (177Lu) Oxodotreotide

Study of Telisotuzumab Adizutecan for Adults with Colorectal Cancer Who Have Positive Circulating Tumor DNA After Treatment but No Visible Cancer on Scans

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years

Evaluating 68Ga-FAPI-46 PET/CT Scanning for Improved Diagnosis in Patients with Pancreatic Cancer or Bile Duct Cancer Eligible for Curative Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate

Hepatitis D

Recruiting

Clinical Trial for Patients with Chronic Hepatitis D: Comparing Brelovitug and Bulevirtide Treatments

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bjt-778

Study on the Effectiveness and Safety of Infigratinib for Children with Hypochondroplasia and Short Stature

Registered drug
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Infigratinib

Neuroblastoma

Recruiting

Study of Temozolomide, Topotecan, Bevacizumab, Irinotecan and Dinutuximab Beta in Patients with High-Risk Relapsed Neuroblastoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Bevacizumab

Obesity+2

Recruiting

Study on Tirzepatide for Women with Overweight or Obesity and Polycystic Ovary Syndrome (PCOS)

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Dydrogesterone

Study on Ersodetug for Patients with Uncontrolled Low Blood Sugar Due to Tumor-Related High Insulin Levels

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anti-(Insulin Receptor) Human Monoclonal Antibody

Study on the Effectiveness of Abatacept for Patients with Giant Cell Arteritis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abatacept

Phenylketonuria

Recruiting

Study of Long-Term Neurocognitive Outcomes in Children with Phenylketonuria Treated with Sepiapterin

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Sepiapterin
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.